CCS technological innovation system dynamics in Norway

CO2 Capture and Storage (CCS) is today seen as a key technology to cut carbon emissions in many hard-to-abate sectors such as energy-intensive processing industries and the waste sector. Although CO2 capture is technically possible, key challenges for realizing CCS persist. Over the past decade, CCS has taken a new direction with more focus on application in energy-intensive industries rather than the energy sector. For CCS value chains to materialize, innovation and implementation thus needs to occur amongst an array of actors, with different innovation modes, institutions, and policy regimes, and with varying sectoral capacities for adaptation and change. There has so far been limited social science research on CCS innovation dynamics, which we suggest approaching as a socio-technical change process. To better understand this process, we draw on the sustainability transitions research field and employ the Technological Innovation System (TIS) framework to study the CCS innovation system in Norway. We find that, overall, the Norwegian CCS TIS displays systemic weaknesses for example in the form of market formation and resource mobilization, yet recent developments suggest a relatively positive momentum for this technological field which is key to meeting Norwegian and global climate mitigation targets.publishedVersio

Increased frequency of rare missense <i>PPP1R3B</i> variants among Danish patients with type 2 diabetes

<div><p>Background</p><p><i>PPP1R3B</i> has been suggested as a candidate gene for monogenic forms of diabetes as well as type 2 diabetes (T2D) due to its association with glycaemic trait and its biological role in glycogen synthesis.</p><p>Objectives</p><p>To study if rare missense variants in <i>PPP1R3B</i> increase the risk of maturity onset diabetes of the young (MODY), T2D or affect measures of glucose metabolism.</p><p>Method</p><p>Targeted resequencing of <i>PPP1R3B</i> was performed in 8,710 samples; MODY patients with unknown etiology (<i>n</i> = 54), newly diagnosed patients with T2D (<i>n</i> = 2,930) and population-based control individuals (<i>n</i> = 5,726, of whom <i>n</i> = 4,569 had normal glucose tolerance). All population-based sampled individuals were examined using an oral glucose tolerance test.</p><p>Results</p><p>Among <i>n</i> = 396 carriers, we identified twenty-three <i>PPP1R3B</i> missense mutations, none of which segregated with MODY. The burden of likely deleterious <i>PPP1R3B</i> variants was significantly increased with a total of 17 carriers among patients with T2D (0.58% (95% CI: 0.36–0.93)) compared to 18 carriers among non-diabetic individuals (0.31% (95% CI: 0.20–0.49)), resulting in an increased risk of T2D (OR (95% CI) = 2.57 (1.14–5.79), <i>p</i> = 0.02 (age and sex adjusted)). Furthermore, carriers with diabetes had less abdominal fat and a higher serum concentration of LDL-cholesterol compared to patients with T2D without rare missense <i>PPP1R3B</i> variants. In addition, non-diabetic carriers had a higher birth weight compared to non-carriers.</p><p>Conclusion</p><p>Rare missense <i>PPP1R3B</i> variants may predispose to T2D.</p></div

Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort study

<p>Abstract</p> <p>Background</p> <p>The optimum oral pharmacological treatment of diabetes mellitus to reduce cardiovascular disease and mortality following myocardial infarction has not been established. We therefore set out to investigate the association between individual oral glucose-lowering drugs and cardiovascular outcomes following myocardial infarction in patients with diabetes mellitus not treated with emergent percutaneous coronary intervention.</p> <p>Materials and methods</p> <p>All patients aged 30 years or older receiving glucose-lowering drugs (GLDs) and admitted with myocardial infarction (MI) not treated with emergent percutaneous coronary intervention in Denmark during 1997-2006 were identified by individual-level linkage of nationwide registries of hospitalizations and drug dispensing from pharmacies. Multivariable Cox regression models adjusted for age, sex, calendar year, comorbidity, and concomitant pharmacotherapy were used to assess differences in the composite endpoint of non-fatal MI and cardiovascular mortality between individual GLDs, using metformin monotherapy as reference.</p> <p>Results</p> <p>The study comprised 9876 users of GLDs admitted with MI. The mean age was 72.3 years and 56.5% of patients were men. A total of 3649 received sulfonylureas and 711 received metformin at admission. The average length of follow-up was 2.2 (SD 2.6) years. A total of 6,171 patients experienced the composite study endpoint. The sulfonylureas glibenclamide, glimepiride, glipizide, and tolbutamide were associated with increased risk of cardiovascular mortality and/or nonfatal MI with hazard ratios [HRs] of 1.31 (95% confidence interval [CI] 1.17-1.46), 1.19 (1.06-1.32), 1.25 (1.11-1.42), and 1.18 (1.03-1.34), respectively, compared with metformin. Gliclazide was the only sulfonylurea not associated with increased risk compared with metformin (HR 1.03 [0.88-1.22]).</p> <p>Conclusions</p> <p>In patients with diabetes mellitus admitted with MI not treated with emergent percutaneous coronary intervention, monotherapy treatment with the sulfonylureas glibenclamide, glimepiride, glipizide, and tolbutamide was associated with increased cardiovascular risk compared with metformin monotherapy.</p

Evaluation of eczema, asthma, allergic rhinitis and allergies among the Grade-1 children of Iqaluit

Additional file 3: Appendix S3. Tested allergens

Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors

Background Suicide is a leading cause of death worldwide, and nonfatal suicide attempts, which occur far more frequently, are a major source of disability and social and economic burden. Both have substantial genetic etiology, which is partially shared and partially distinct from that of related psychiatric disorders. Methods We conducted a genome-wide association study (GWAS) of 29,782 suicide attempt (SA) cases and 519,961 controls in the International Suicide Genetics Consortium (ISGC). The GWAS of SA was conditioned on psychiatric disorders using GWAS summary statistics via multitrait-based conditional and joint analysis, to remove genetic effects on SA mediated by psychiatric disorders. We investigated the shared and divergent genetic architectures of SA, psychiatric disorders, and other known risk factors. Results Two loci reached genome-wide significance for SA: the major histocompatibility complex and an intergenic locus on chromosome 7, the latter of which remained associated with SA after conditioning on psychiatric disorders and replicated in an independent cohort from the Million Veteran Program. This locus has been implicated in risk-taking behavior, smoking, and insomnia. SA showed strong genetic correlation with psychiatric disorders, particularly major depression, and also with smoking, pain, risk-taking behavior, sleep disturbances, lower educational attainment, reproductive traits, lower socioeconomic status, and poorer general health. After conditioning on psychiatric disorders, the genetic correlations between SA and psychiatric disorders decreased, whereas those with nonpsychiatric traits remained largely unchanged. Conclusions Our results identify a risk locus that contributes more strongly to SA than other phenotypes and suggest a shared underlying biology between SA and known risk factors that is not mediated by psychiatric disorders.Peer reviewe